IRVINE, Calif.--(BUSINESS WIRE)--California Stem Cell, Inc. (CSC) today announced that it has signed a contract to supply international drug discovery organization BioFocus DPI, the service division of Galapagos, with its MOTORPLATE™ 96 assay-ready well plates, containing motor neuron progenitors (MNPs) derived from human embryonic stem cells (hESC). BioFocus DPI will use the high purity, clinical grade human motor neurons to perform assay development and screening for amyotrophic lateral sclerosis (ALS or “Lou Gehrig’s Disease”) drug discovery on behalf of The ALS Association’s TREAT ALS™ drug discovery and clinical trials program.
